B
XFOR icon

Braidwell’s X4 Pharmaceuticals XFOR Stock Holding History

Braidwell’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.6M Sell
2,922,754
-350,200
-11% -$1.44M 0.5% 63
2026
Q1 		$13.5M Sell
3,272,954
-95,950
-3% -$359K 0.45% 65
2025
Q4 		$13.5M Buy
+3,368,904
New +$12.2M 0.43% 60

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Braidwell's XFOR Position: Q2 2026 in Review

Braidwell reduced its X4 Pharmaceuticals (XFOR) stake by 11% in Q2 2026, selling an estimated $1.44M and leaving 2,922,754 shares worth $13.6M. The position accounts for 0.5% of the portfolio, ranked #63.

Braidwell first reported a position in XFOR in Q4 2025 and has held it in 3 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Braidwell held 2,922,754 shares of X4 Pharmaceuticals worth $13.6M as of Q2 2026.
  • Braidwell sold 350,200 X4 Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
  • X4 Pharmaceuticals made up 0.5% of Braidwell's portfolio in Q2 2026, its #63 holding.
  • Braidwell first reported a position in X4 Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.